<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136417</url>
  </required_header>
  <id_info>
    <org_study_id>21-009613</org_study_id>
    <nct_id>NCT05136417</nct_id>
  </id_info>
  <brief_title>Study of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device</brief_title>
  <official_title>Safety and Feasibility of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device: The ICE WATCHMAN Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to to assess the feasibility and safety of left atrial&#xD;
      appendage (LAA) occlusion with the WATCHMAN FLXâ„¢ device using a standardized intra-procedural&#xD;
      intracardiac echocardiography (ICE) protocol under moderate sedation for procedural guidance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful implantation of WATCHMAN FLX device</measure>
    <time_frame>45 days post procedure</time_frame>
    <description>Number of successfully implanted WACHMAN FLX devices. Implant success is defined as confirmation of the device-specified release PASS (Position, Anchor, Size, Seal) criteria, successful device release, and adequate seal (defined as a residual leak &lt;5 mm) as assessed by a core lab interpretation of the TEE 45 days post-implant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major complications</measure>
    <time_frame>45 days post procedure</time_frame>
    <description>Number of major complications as defined as major bleeding (intracranial bleeding, or bleeding requiring blood transfusion), pericardial effusion requiring pericardiocentesis or surgery, device embolization, procedural-related stroke, or procedural related death).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Left Atrial Appendage Occlusion</condition>
  <arm_group>
    <arm_group_label>left atrial appendage (LAA) occlusion with the WATCHMAN FLX device using (ICE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patients undergoing LAA closure with the WATCHMAN FLX utilizing an intra-procedural ICE probe under moderate sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intra-procedural intracardiac echocardiography (ICE) probe</intervention_name>
    <description>placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.</description>
    <arm_group_label>left atrial appendage (LAA) occlusion with the WATCHMAN FLX device using (ICE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients is eligible to undergo WATCHMAN device implant procedure.&#xD;
&#xD;
          -  The patient is eligible for short term anticoagulation therapy.&#xD;
&#xD;
          -  Ability to tolerate the procedure without the need for general anesthesia as assessed&#xD;
             by the treating physician(s).&#xD;
&#xD;
          -  Ability to give informed consent for the procedure.&#xD;
&#xD;
          -  The patient is able and willing to undergo the procedure under moderate sedation.&#xD;
&#xD;
          -  The patient is able and willing to return for required 45-day TEE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has contraindication for short term anticoagulation.&#xD;
&#xD;
          -  The patient has history of a hypercoagulable state per medical record documentation.&#xD;
&#xD;
          -  Pregnancy or planning to get pregnant during the investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Adnan Alkhouli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Structural Heart Research Team</last_name>
    <phone>507-255-6133</phone>
    <email>konwinski.craig@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mohamad Adnan Alkhouli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

